独家：MIRA制药公司即将被收购的减肥药在动物研究中逆转肥胖标志物并减少尼古丁渴求-动脉网

EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study

benzinga 等信源发布 2025-06-30 07:20



可切换为仅中文







MIRA Pharmaceuticals, Inc.

米拉制药公司

MIRA

米拉

on Monday revealed new animal study results from SKNY-1, a next-generation oral therapeutic.

周一公布了下一代口服治疗药物SKNY-1的新动物研究结果。

The company says the findings further support the advancement of SKNY-1 toward Investigational

公司表示，这些发现进一步支持了SKNY-1向研究性新药的推进。

New Drug (IND) enabling studies

新药（IND）启用研究

。

With obesity and smoking representing two of the leading causes of preventable death and a combined global market opportunity exceeding $200 billion, MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending the

鉴于肥胖和吸烟是可预防死亡的两大主要原因，且全球市场机会合计超过2000亿美元，MIRA计划将SKNY-1作为潜在的基石资产进行优先考虑，等待

completion of the acquisition

收购的完成

的

SKNY Pharmaceuticals, Inc

斯凯尼制药公司

。

In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and craving for high-calorie diets, and reversal of nicotine-seeking behavior—all achieved within six days of oral treatment.

在模仿人类肥胖和渴望行为的斑马鱼模型中，SKNY-1 在口服治疗的六天内实现了减重、抑制食欲和对高热量饮食的渴望，并逆转了尼古丁寻求行为。

Also Read:

另请阅读：

EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study

独家：MIRA制药公司主导项目Ketamir-2在FDA要求的研究中显示无脑毒性

SKNY-1 is being developed as an oral alternative to GLP-1 injectables, which are often limited by nausea, GI discomfort, injection reaction, and growing concerns around muscle loss.

SKNY-1 正在被开发为 GLP-1 注射剂的口服替代品，GLP-1 注射剂常因恶心、胃肠道不适、注射反应以及日益引发的对肌肉流失的担忧而受到限制。

Key Results

关键结果

SKNY-1 reduced body weight by approximately 30% after six days of oral treatment. Treated animals weighed about 10% less than healthy controls. The company said the weight loss was not accompanied by muscle density changes.

SKNY-1 在六天的口服治疗后使体重减少了约 30%。经过治疗的动物比健康对照组轻了约 10%。公司表示，这种体重减轻并未伴随肌肉密度的变化。

Treated animals showed an increase in breathing rate, which is a reliable signal that their metabolism was speeding up.

接受治疗的动物呼吸频率增加，这是它们新陈代谢加快的可靠信号。

In untreated obese animals, fat buildup in the liver was about 50% higher than normal. SKNY-1 reversed this buildup, bringing liver fat back to healthy levels. At the same time, cholesterol levels—including LDL (‘bad' cholesterol) and HDL (‘good' cholesterol)—also returned to normal without affecting fat levels in the blood..

在未经治疗的肥胖动物中，肝脏中的脂肪堆积比正常情况高出约50%。SKNY-1逆转了这种脂肪堆积，使肝脏脂肪恢复到健康水平。同时，胆固醇水平（包括低密度脂蛋白（“坏”胆固醇）和高密度脂蛋白（“好”胆固醇））也恢复正常，且不影响血液中的脂肪水平。

Obese animals were eating 2–3 times more high-calorie food than normal. SKNY-1 dose-dependently reduced the behavior—high-dose animals ate less than healthy controls. The drug also made the animals less likely to pursue food in stressful environments and reduced obsessive food-seeking in tests designed to measure craving..

肥胖动物摄入的高热量食物是正常动物的2-3倍。SKNY-1以剂量依赖性方式减少了这种行为——高剂量组的动物进食量甚至低于健康对照组。该药物还降低了动物在压力环境中追求食物的可能性，并在设计用于测量渴求程度的测试中减少了强迫性的觅食行为。

SKNY-1 significantly reduced the desire to seek out and consume nicotine. At the high dose, their behavior matched that of healthy animals with no nicotine craving.

SKNY-1显著降低了寻找和消费尼古丁的欲望。在高剂量下，它们的行为与没有尼古丁渴望的健康动物相当。

Obese animals had extremely high levels of leptin (a hunger-regulating hormone) and unusually low levels of ghrelin (the ‘hunger signal'). SKNY-1 normalized both hormones, improving the body's ability to regulate hunger and energy use.

肥胖动物的瘦素（一种调节饥饿的激素）水平极高，而胃饥饿素（“饥饿信号”）水平异常低。SKNY-1使这两种激素恢复正常，提高了身体调节饥饿和能量使用的能力。

Obese animals had too much dopamine in their brains, likely tied to increased reward and cravings. SKNY-1 reduced these dopamine levels—but only at the lower dose. The high dose did not affect dopamine, suggesting the drug can reduce cravings without overstimulating the brain.

肥胖动物大脑中多巴胺过多，可能与奖励和渴望增加有关。SKNY-1降低了这些多巴胺水平——但仅在较低剂量时有效。高剂量并未影响多巴胺，表明该药物可以减少渴望而不会过度刺激大脑。

Price Action:

价格行为：

MIRA stock is down 1.20% to $1.23 during the premarket session at the last check on Monday.

麦拉股票在周一最后一次检查时，盘前交易时段下跌1.20%，至1.23美元。